Know Cancer

or
forgot password

Phase II Study of the Response Rate of Induction Chemotherapy With Gemcitabine and Carboplatin for Operable Non-small Cell Lung Cancer Before Surgery


Phase 2
18 Years
75 Years
Open (Enrolling)
Both
Lung Neoplasms

Thank you

Trial Information

Phase II Study of the Response Rate of Induction Chemotherapy With Gemcitabine and Carboplatin for Operable Non-small Cell Lung Cancer Before Surgery


Inclusion Criteria:



- Histologically or cytologically proven, newly diagnosed primary bronchogenic
non-small cell lung cancer

- Measurable or evaluable tumour on chest X-ray or CT scan.

- No multiple ipsilateral or contralateral parenchymal tumours

- Stage I(exceptT1N0),II,IIIa disease as shown by PET-CT

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

pathological response rate

Outcome Time Frame:

12 months

Principal Investigator

Siu Kie Au, Dr

Investigator Role:

Principal Investigator

Investigator Affiliation:

Department of Clinical Oncology, Queen Elizabeth Hospital

Authority:

Hong Kong: Ethics Committee

Study ID:

(193-h)in QE/EC/I

NCT ID:

NCT00563160

Start Date:

May 2005

Completion Date:

February 2007

Related Keywords:

  • Lung Neoplasms
  • lung cancer
  • Neoplasms
  • Carcinoma, Non-Small-Cell Lung
  • Lung Neoplasms

Name

Location